31 studies found for:    celgene abi-007 | Open Studies
Show Display Options
Rank Status Study
1 Not yet recruiting Safety and Efficacy Study of Abraxane as Maintenance Treatment After Abraxane Plus Carboplatin in 1st Line Stage IIIB / IV Squamous Cell Non-small Cell Lung Cancer
Condition: Squamous Cell Carcinoma, Non-Small-Cell Lung
Interventions: Drug: Abraxane (Induction);   Drug: Carboplatin (Induction);   Drug: Abraxane (Maintenance);   Other: Best Supportive Care (Maintenance)
2 Recruiting Safety and Efficacy Study of Abraxane Plus Gemcitabine in Chinese Patients With Metastatic Pancreatic Cancer
Condition: Pancreatic Neoplasms
Interventions: Drug: Abraxane;   Drug: Gemcitabine
3 Recruiting To Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors
Conditions: Neuroblastoma;;   Rhabdomyosarcoma;;   Ewing's Sarcoma;;   Ewing's Tumor;;   Sarcoma, Ewing's;;   Sarcomas, Epitheliod;;   Sarcoma, Soft Tissue;;   Sarcoma, Spindle Cell;;   Melanoma;;   Malignant Melanoma;;   Clinical Oncology;;   Oncology, Medical;;   Pediatrics, Osteosarcoma;;   Osteogenic Sarcoma;;   Osteosarcoma Tumor;;   Sarcoma, Osteogenic;;   Tumors;;   Cancer;;   Neoplasia;;   Neoplasm;;   Histiocytoma;;   Fibrosarcoma;;   Dermatofibrosarcoma
Intervention: Drug: nab-paclitaxel
4 Recruiting Evaluate Risk/Benefit of Nab Paclitaxel in Combinaton With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer
Conditions: Breast Tumor;   Breast Cancer;   Cancer of the Breast;   Estrogen Receptor- Negative Breast Cancer;   HER2- Negative Breast Cancer;   Progesterone Receptor- Negative Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer;   Triple-negative Breast Cancer;   Triple-negative Metastatic Breast Cancer;   Metastatic Breast Cancer
Interventions: Drug: nab-Paclitaxel 125 mg/m2 plus carboplatin AUC 2 in triple negative metastatic breast cancer (TNMBC) subjects;   Drug: Carboplatin AUC 2;   Drug: gemcitabine 1000 mg
5 Recruiting Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)
Conditions: Pancreatic Neoplasms;   Digestive System Neoplasms;   Neoplasms by Site;   Neoplasms;   Endocrine Gland Neoplasms;   Pancreatic Diseases;   Digestive System Diseases;   Endocrine System Diseases;   Gemcitabine;   Antimetabolites, Antineoplastic
Interventions: Drug: nab-Paclitaxel 125 mg/m2;   Drug: gemcitabine 1000 mg/m2
6 Recruiting A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors
Condition: Relapsed or Refractory Solid Tumors
Interventions: Drug: CC-486 plus Carboplatin;   Drug: CC-486 plus ABI-007;   Drug: CC-486
7 Recruiting A Study to Collect Survival Data on Patients Previously Enrolled in Abraxane Pancreatic Cancer Study CA046.
Condition: Pancreatic Cancer
Intervention:
8 Not yet recruiting Phase 2 Study With Abraxane (Nab®Paclitaxel) in Metastatic Colorectal Cancer
Condition: Colorectal Neoplasms
Intervention: Drug: ABI-007
9 Recruiting Phase I & II Trial of Intravesicular Abraxane for Treatment-refractory Bladder Cancer
Condition: Bladder Cancer
Intervention: Drug: Paclitaxel, nanoparticle albumin-bound
10 Recruiting Phase I/II Trial of the Combination of Lenalidomide (Revlimid) and Nab-paclitaxel (Abraxane) in the Treatment of Relapsed/Refractory Multiple Myeloma
Condition: Relapsed or Refractory Multiple Myeloma
Interventions: Drug: Lenalidomide;   Drug: nab-paclitaxel
11 Recruiting A Phase I/II Study of Nab-Paclitaxel, or Paclitaxel, Plus Carboplatin With Concurrent Radiation Therapy Followed by Consolidation in Patients With Favorable Prognosis Inoperable Stage IIIA/B NSCLC
Condition: INOPERABLE STAGE IIIA/B NON-SMALL CELL LUNG CANCER
Interventions: Drug: NAB-PACLITAXEL;   Drug: PACLITAXEL
12 Recruiting Phase II Study of Abraxane Plus Ipilimumab in Patients With Metastatic Melanoma
Condition: Melanoma
Interventions: Drug: ABI-007;   Drug: Ipilimumab;   Behavioral: Phone Call
13 Recruiting A Phase I Trial of Abraxane, Cisplatin and 5-Fluorouracil Along With Chemoradiotherapy in Advanced Head and Neck Cancer
Condition: Head and Neck Cancer
Intervention: Drug: ABI-007
14 Recruiting Efficacy of ABI-007 Plus Gemcitabine or sLV5FU2 as First-line Therapy in Patients With Metastatic Pancreatic Cancer
Condition: Metastatic Pancreatic Cancer
Interventions: Drug: ABI-007;   Drug: Gemcitabine;   Drug: simplified LV5FU2
15 Recruiting Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab With Lapatinib and Paclitaxel
Condition: Breast Cancer
Interventions: Drug: Trastuzumab Emtansine;   Drug: Trastuzumab;   Drug: Lapatinib;   Drug: Abraxane;   Drug: Paclitaxel
16 Recruiting Abraxane in CIMP-High Colorectal and Small Bowel Adenocarcinomas
Conditions: Colorectal Cancer;   Cancer of Gastrointestinal Tract
Intervention: Drug: Abraxane
17 Not yet recruiting Effect on Tumor Perfusion of a Chemotherapy Combining Gemcitabine and Nab-paclitaxel (Abraxane) in Pancreatic Cancer
Conditions: Pancreatic Adenocarcinoma Resectable;   Pancreatic Adenocarcinoma Locally Advanced;   Pancreatic Adenocarcinoma Metastatic
Interventions: Drug: Gemcitabine;   Drug: Abraxane
18 Not yet recruiting Treatment With Nab-paclitaxel in Cutaneous SCC
Condition: Cutaneous Squamous Cell Carcinoma
Intervention: Drug: nab-paclitaxel
19 Recruiting A Phase I/II Clinical Trial of Vidaza With Abraxane in the Treatment of Patients With Advanced or Metastatic Solid Tumors and Breast Cancer
Conditions: Advanced or Metastatic Solid Tumors;   Advanced or Metastatic Breast Cancer
Interventions: Drug: Azacitidine (Vidaza);   Drug: Nab-paclitaxel (Abraxane)
20 Recruiting Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Panitumumab;   Drug: Nab-paclitaxel;   Drug: Carboplatin;   Drug: 5-Fluorouracil;   Drug: Epirubicin;   Drug: Cyclophosphamide

Previous Page Studies Shown (1-20) Next Page (21-31) Show next page of results
Indicates status has not been verified in more than two years